Phase 4 N=84 Mirabegron and Urinary Urgency Incontinence
Overactive Bladder
Primary: Response to Therapy — 15; 29 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=50 Study to Gather Information on the Acceptability of a New Flavor System With Increasing Levels of 2, 4, 6 g or Higher of Mannitol for PEG 3350 in Subjects Having Infrequent Bowel Movements.
Constipation
Primary: Number of Participants With the Opinion of the Products' Flavor — 1; 0; 0; 0 Participants
Phase 4 N=350 Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care
Hepatitis C · Substance Use Disorders · Substance Abuse, Intravenous
Primary: SVR 12 — 24; 15; 47; 1 Participants
Phase 4 N=40 Genicular Nerve Block for Total Knee Arthroplasty
Post-operative Pain
Primary: Opioid Consumption at 24 Hours Post-op — 22.9; 58.1 milligrams of oral morphine equivalents
Phase 4 N=60 The ISLAND Study: InSuLa Assessed Needs for Depression
Depression
Primary: Number of Remission From Major Depressive Episode Events — 15; 4 number of events
Phase 4 N=17 Imaging of 3D Innervation Zone Distribution in Spastic Muscles From High-density Surface EMG Recordings
Spasticity
Primary: Spasticity as Assessed by Reflex Torque of Elbow Flexors — 2.32; 2.04; 2.41; 3.11 Newton meter (n-m)
Phase 4 N=95 An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study
Neoplasms
Primary: Percentage of Participants With Adverse Events — 90.9; 78.0; 71.4; 100.0 percentage of participants
Phase 4 N=30 Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia
Homozygous Familial Hypercholesterolemia HoFH
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 10 Participants
Phase 4 N=55 Mechanisms and Treatment of Intradialytic Hypertension
Intradialytic Hypertension
Primary: Endothelial Progenitor Cells — 0.052; 0.034; 0.027; 0.059 % of mononuclear cells
Phase 4 N=99 Efficacy of Ipack Block and Surgeon's Joint Infiltration in Total Knee Arthroplasty
Osteo Arthritis Knee
Primary: Narcotic Consumption — 15.87; 13.67 morphine equivalents, mg
Phase 4 N=60 Antibiotic Elution in Total Knee Arthroplasty
Total Knee Replacement
Primary: Amount of Vancomycin and Tobramycin Eluted From Hand Mixed Cement With Both Antibiotics After Total Knee Arthroplasty — 23.9; 30.6; 12.6; 16.2 mg/mL
Phase 4 N=12 Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan
Systemic Sclerosis · Shortness of Breath · Pulmonary Hypertension
Primary: Change in Exercise Pulmonary Hemodynamics From Baseline to Week 24 — 37.4 mmHg — p=.0008
Phase 4 N=65 Efficacy Study of Vaginal Mesh for Anterior Prolapse
Vaginal Prolapse · Uterine Prolapse · Cystocele
Primary: The Primary Outcome Measure for Objective Treatment Success is Anterior Prolapse, Point Ba at Stage 0 or 1 (Defined as Maximal Descent of the Anterior Wall to Greater…
Phase 4 N=84 Tranexamic Acid Dosing for Total Joint Arthroplasty
Arthropathy of Hip · Arthropathy of Knee
Primary: Change in Hemoglobin From Baseline to the First Post-operative Day (POD#1) — 2.15; 2.06; 2.11 g/dl
Phase 4 N=72 Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy
Heart Failure
Primary: Safety Endpoint: % of Patients With Non-surgical Bleeding at 6 Months Post HeartMate II Implant — 12; 15 Participants